Last reviewed · How we verify
Physician's Choice medications
Physician's Choice medications are a class of treatments that provide a choice between different medications for a specific condition.
Physician's Choice medications are a class of treatments that provide a choice between different medications for a specific condition. Used for Multiple Indications.
At a glance
| Generic name | Physician's Choice medications |
|---|---|
| Also known as | corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib |
| Sponsor | Swedish Orphan Biovitrum |
| Drug class | Physician's Choice |
| Modality | Small molecule |
| Therapeutic area | Multiple Therapeutic Areas |
| Phase | Phase 3 |
Mechanism of action
Physician's Choice medications allow healthcare providers to select the most appropriate treatment option for a patient based on their individual needs and medical history. This approach can lead to better patient outcomes and improved quality of care.
Approved indications
- Multiple Indications
Common side effects
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) (PHASE2, PHASE3)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician's Choice medications CI brief — competitive landscape report
- Physician's Choice medications updates RSS · CI watch RSS
- Swedish Orphan Biovitrum portfolio CI